Galectin Therapeutics and CTI Announce Positive New Psoriasis and Atopic Dermatitis Clinical Data

“We are very pleased to continue our collaboration with Galectin through this exciting trial that is showing promise for patients with severe skin diseases,” according to Joseph McCafferty, Vice President Global Business Development at CTI. “Dr. Traber and his Galectin colleagues have been tremendous to work with and we are privileged to be a partner on several of their life-changing programs.”

Bexion and CTI Announce Collaboration on First-in-Human Trial for the Treatment of Cancer

"We are really enthused to be partnering with Bexion Pharmaceuticals,” according to Timothy Schroeder, CTI Founder and CEO. “They are an innovative organization with very strong regional ties – the drug was initially developed and licensed from Cincinnati Children’s Hospital Medical Center, early funding has predominantly come from the region, and the management and board have strong local connections. This program has the potential to be a game changer in the cancer arena.”

CTI Announces Site of New Global Headquarters

CTI will relocate its corporate headquarters from the Cincinnati suburb of Blue Ash, Ohio 17 miles south to Covington, Kentucky's RiverCenter complex, where it will initially occupy approximately 125,000 square feet. The relocation will help the company consolidate its locations and facilitate future growth.

"As we continue to expand the company presence in the Tri-state area, we hope to become a model for other companies, in growing our footprint throughout this incredibly rich region. It is a transformative time in the company's history, and we will look back positively on this decision and its impact on the company's ability to move life-changing therapies to patients around the world,” according to Timothy J. Schroeder, CTI Chief Executive Officer. 

Global Clinical Trials Firm CTI to Locate Headquarters in Covington, Create 500 Kentucky-Resident Jobs

CTI plans to move its headquarters from the Cincinnati suburb of Blue Ash, Ohio, closer to the region’s urban center. It will lease about 125,000 square feet in the RiverCenter building. The relocation will help the company consolidate its locations and facilitate future growth.

“We’re thrilled for CTI to be starting a new chapter at RiverCenter,” said Timothy Schroeder, CEO of CTI. “We feel that this location will be a state-of-the-art headquarters for our staff, enabling collaboration and innovation. This site allows us to retain and grow the most talented team in the industry who are helping to develop some of the most innovative life-changing therapies.”

CTI Announces Formation of Korean Subsidiary and Opening of Seoul Office

“The expansion into Korea is part of efforts to increase capacity for clinical research in one of Asia’s fastest-growing countries for drug development,” according to Patrick Earley, Vice President, International. “We have been working with leading Korean academic medical centers for a number of years, as well as collaborating with innovative Korean biotechnology companies. This expansion will only further enhance the relationships and collaborations we have in the country.”

CTI Clinical Research Associates Are "Critical In The Success That We Have Had In Our Study"

Global clinical monitoring coverage for CTI, is built around the philosophy of providing therapeutic expertise to our sponsors. CTI Clinical Research Associates (CRAs) have significant experience working with complex studies and critically ill patients. Our staff has decades of experience in research and nursing outside of their CRA experience. With an average retention rate of over 95%, our CRAs are able to see their studies through from start‐up to close‐out.


Rare Disease / Orphan Disease

CTI is a leader in rare disease and orphan disease research with approximately 80% of our work falling into this category.

Learn More


CTI is a leader in this field with contributions to nearly all transplant-related therapies on the market today.

Learn More

Regulatory Submissions & Applications

CTI’s has continued proven success in numerous approved drug and device applications. We have more than 100 drug approvals in our history.

Learn More

Participate in a Trial

Icon Careers Small Retina

CTI CRC is looking for volunteers to participate in our current trials. 

Learn More

Join our Team

Icon Briefcase Small Retina

At CTI, our employees are offered the opportunity to make a difference for themselves, their families, and in the medical community in which we work.

Learn More